aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.
| Revenue (Most Recent Fiscal Year) | $0.23M |
| Net Income (Most Recent Fiscal Year) | $-64.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.17 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -27243.40% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -87.09% |
| Return on Assets (Trailing 12 Months) | -64.77% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.79 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.83 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.86 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.81 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 89.00M |
| Free Float | 85.71M |
| Market Capitalization | $462.82M |
| Average Volume (Last 20 Days) | 2.25M |
| Beta (Past 60 Months) | 0.88 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |